Company News - China Shenhua (01088.HK) reported coal sales of 389.5 million tons for the first 11 months, a decrease of 7.7% year-on-year. November sales were 37 million tons, down 3.6% year-on-year [1] - China Metallurgical Group (01618.HK) signed new contracts worth RMB 958.13 billion in the first 11 months, an 8.6% decrease year-on-year, with overseas contracts amounting to RMB 75 billion, a 0.4% increase year-on-year [1] - China Eastern Airlines (00670.HK) saw a 6.51% year-on-year increase in passenger capacity in November, with passenger turnover up 10.35% year-on-year and a seat load factor of 87.37%, up 3.04 percentage points year-on-year [1] - China Southern Airlines (01055.HK) reported an 8.68% year-on-year increase in passenger capacity in November, with passenger turnover up 10.42% year-on-year and a seat load factor of 86.29%, up 1.36 percentage points year-on-year [1] - New China Life Insurance (01336.HK) recorded cumulative original insurance premium income of RMB 188.85 billion for the first 11 months, a 16% year-on-year increase [1] - AOS Group (01161.HK) announced annual results for the year ending September 30, 2025, with revenue of approximately HKD 981 million, a decrease of 0.19% year-on-year, and a net profit of HKD 80.887 million, a 19% year-on-year increase [1] - Hopson Development Holdings (00754.HK) reported total contract sales of approximately RMB 14.27 billion for the first 11 months, an 8.91% decrease year-on-year [1] - Agile Group (01813.HK) had a pre-sale amount of RMB 511 million in November, a decrease of 21.4% year-on-year [1] - Galen Pharmaceuticals (01672.HK) is expected to become a best-in-class oral small molecule IL-17 inhibitor, with positive topline results from its Phase I study in the U.S. [1] - Bole Technology (02592.HK) submitted a new drug clinical trial application for CBT-199 to the U.S. FDA [1] - China Supply Chain Industry (03708.HK) signed a strategic cooperation framework agreement with Golden Energy regarding digital assets [1] - Times China Holdings (01233.HK) had its liquidation petition withdrawn [1] - Botai Car Union (02889.HK) received a first project designation notice from a leading domestic new energy vehicle client [1] Buyback Activities - Haijia Medical (06078.HK) plans to repurchase 10% of its issued shares, with a repurchase amount of no less than RMB 300 million [1] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with repurchase prices ranging from HKD 602.5 to HKD 608 [1] - Xiaomi Group (01810.HK) repurchased 7.2 million shares for HKD 302 million, with repurchase prices ranging from HKD 41.78 to HKD 42 [1] Share Cancellation - Pacific Shipping (02343.HK) canceled 23.739 million repurchased shares [2]

Core Viewpoint - Haijia Medical (06078.HK) announced a general authorization for share repurchase at the upcoming annual general meeting on June 27, 2025, allowing the company to repurchase up to 61.8499 million shares, representing 10% of the total issued shares as of the meeting date [1] Group 1 - The company’s stock closed at HKD 11.63 on December 15, 2025, with an increase of 0.26% and a trading volume of 4.5822 million shares, resulting in a turnover of HKD 53.1235 million [1] - The investment banks predominantly rate the stock as a buy, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for Haijia Medical [1] Group 2 - Haijia Medical has a market capitalization of HKD 7.175 billion and ranks 7th in the medical services sector II [1] - Key performance indicators for the company are summarized in the accompanying table [1]

本公司认为，股份目前的交易价格并未反映其内在价值或本公司的实际业务前景。因此，本公司董事会 已议决利用购回授权，以不时在公开市场上按不少于人民币3亿元的总价格购回股份。本公司认为，建 议股份购回将展现本公司对其自身业务发展前景充满信心，而本公司现有财务资源将足以支持实施建议 股份购回，同时维持稳健的财务状况。本公司将视市场情况，持续优化股东回报，在回购、分红及併购 扩张中做出更高效的、更有利于股东价值的资本配置安排。 海吉亚医疗(06078)发布公告，就有关本公司股东于本公司于2025年6月27日举行的股东周年大会授出的 购回本公司股份的一般授权的相关事宜。根据购回授权，本公司获准于香港联合交易所有限公司购回最 多6184.99万股股份，占于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 ...

智通财经APP讯，海吉亚医疗(06078)发布公告，就有关本公司股东于本公司于2025年6月27日举行的股 东周年大会授出的购回本公司股份的一般授权的相关事宜。根据购回授权，本公司获准于香港联合交易 所有限公司购回最多6184.99万股股份，占于股东周年大会日期已发行股份(不包括库存股份)总数的 10%。 本公司认为，股份目前的交易价格并未反映其内在价值或本公司的实际业务前景。因此，本公司董事会 已议决利用购回授权，以不时在公开市场上按不少于人民币3亿元的总价格购回股份。本公司认为，建 议股份购回将展现本公司对其自身业务发展前景充满信心，而本公司现有财务资源将足以支持实施建议 股份购回，同时维持稳健的财务状况。本公司将视市场情况，持续优化股东回报，在回购、分红及併购 扩张中做出更高效的、更有利于股东价值的资本配置安排。 ...

格隆汇12月15日丨海吉亚医疗(06078.HK)公告，公司认为股份目前的交易价格并未反映其内在价值或公 司的实际业务前景。因此，公司董事会已议决利用购回授权，以不时在公开市场上按不少于人民币300 百万元的总价格购回股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Hygeia Healthcare Holdings Co., Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 （股 份 代 號：6078） 自願性公告 建議於市場上購回股份 本公司股東及潛在投資者務請留意，本公司是否行使任何購回授權將視乎市 況及將由董事會全權酌情決定。本公司概不保證任何股份購回的時間、數量或 價格，亦不保證會否作出任何購回。本公司股東及潛在投資者於買賣本公司證 券時務請審慎行事。 承董事會命 本公告乃由海吉亞醫療控股有限公司（「本公司」）自願作出。 茲提述本公司日期為二零二五年六月二十七日的公告，內容有關（其中包括） 本 公 司 股 東 於 本 公 司 於 二 零 二 五 年 六 月 二 十 七 日 舉 行 的 股 東 週 年 大 會（「股 東週年大會」）授 出 的 購 回 本 公 司 股 份（「股 份」）的 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in Hai Ji Ya Medical, indicating strong investor interest in the company [1] Group 1: Southbound Fund Activity - On December 9, southbound funds increased their holdings by 351,800 shares of Hai Ji Ya Medical (06078.HK) [1] - Over the past five trading days, there have been four days of net increases, totaling 1,407,400 shares [1] - In the last 20 trading days, there were 13 days of net increases, amounting to 6,962,000 shares [1] - As of now, southbound funds hold 212 million shares of Hai Ji Ya Medical, representing 34.22% of the company's issued ordinary shares [1] Group 2: Company Overview - Hai Ji Ya Medical Holdings Limited primarily provides medical services through two business segments [2] - The hospital business segment offers comprehensive oncology diagnosis and treatment services, including radiotherapy, chemotherapy, surgery, and targeted therapy [2] - The company gradually covers all stages of cancer diagnosis, treatment, and rehabilitation [2] - The other business segment focuses on various other operations [2] - The company mainly operates in the domestic market [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 海吉亞醫療控股有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定 ...

Group 1 - Southbound funds increased their holdings in Hai Ji Ya Medical (06078.HK) by 2.039 million shares on November 20, 2025, marking a 0.98% increase [1][2] - Over the past five trading days, there have been four days of net increases in holdings, totaling 5.2528 million shares [1][2] - In the last 20 trading days, there were 15 days of net increases, accumulating to 12.1438 million shares [1][2] Group 2 - As of now, southbound funds hold 210 million shares of Hai Ji Ya Medical, representing 34.01% of the company's total issued ordinary shares [1][2] - Hai Ji Ya Medical Holdings Limited primarily provides medical services through two business segments, focusing on comprehensive cancer diagnosis and treatment services [2] - The hospital business segment offers multidisciplinary medical services related to cancer, including radiotherapy, chemotherapy, surgery, and targeted therapies, covering all stages of cancer diagnosis, treatment, and rehabilitation [2]

Group 1 - Southbound funds increased their holdings in Hai Ji Ya Medical (06078.HK) by 520,800 shares on November 6, 2025, marking a 0.26% change [1][2] - Over the past five trading days, southbound funds have increased their holdings on four occasions, with a total net increase of 3,135,000 shares [1][2] - In the last 20 trading days, there have been 14 days of net increases, totaling 6,655,400 shares [1][2] Group 2 - As of now, southbound funds hold 203 million shares of Hai Ji Ya Medical, representing 32.85% of the company's total issued ordinary shares [1][2] - Hai Ji Ya Medical Holdings Limited primarily engages in medical services, focusing on a comprehensive one-stop diagnosis and treatment service for cancer [2] - The company operates two segments: the hospital business, which provides multidisciplinary medical services centered around oncology, and other business segments [2]